SPRAVATO™ (esketamine) CIII – Nasal Spray
MUST BE DONE IN APA FORMAT
ALL APA FORMAT THROUGOUT
The paper must include the following content information:
First in class, or not first in class
Common side effects profile
Make sure you explain the special considerations that your chosen drug has on the unique populations/client groups listed below.
Special considerations should include absorption, clearance/elimination, distribution, metabolism half-life, loading dose, route of drug administration, and steady state.Pediatric PatientsPediatric patients are not little adults. There are special pharmacokinetic and pharmacodynamics variations in this patient group. Their reaction to medication can be very unpredictable. Accurate dosing is the key due to their limited body mass. Geriatric PatientsGeriatric patients have altered pharmacokinetic and pharmacodynamics responses to medication. The process of aging and disease will change how the body responds to drug therapy. Memory limitations and increased sensitivity to drug therapy may cause unique problems with this population.Patients With Renal Dysfunction Many medications are excreted through the renal glands or metabolized and excreted renally. Dosage adjustment is the key in this population. Many agents may cause nephrotoxicity.Patients With Liver Dysfunction Liver disease produces alterations in the physiology of the drugs’ pharmacokinetics in the body. Special attention should be given to all drugs used in this client population Obese PatientsObese patients have alterations in their pharmacokinetic and pharmacodynamic response to medication. Many comorbidities and altered nutritional status can be seen as responses to taking these medications. Accurate dosing is paramount.Pregnancy/LactationPregnancy and lactation can be challenging. Concerns of effects to the unborn fetus must be considered. Will treating the mother harm the unborn fetus or nursing infant?